Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Betamethasone
Drug ID BADD_D00260
Description Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties.[A192444] It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders.[A192444] Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.[A192444]
Indications and Usage As a member of the corticosteroid family, betamethasone is indicated for the treatment of several inflammatory conditions. As topical monotherapy, betamethasone is indicated to relieve pruritic and inflammatory symptoms of corticosteroid-responsive-dermatoses.[L11991,L10782,L11997] Betamethasone can be used topically in combination with a vitamin D analog such as calcipotriene to treat plaque psoriasis.[L12000] The corticosteroid is also available as an injectable suspension and can be used to manage a range of inflammatory conditions including endocrine disorders, gastrointestinal disorders, and rheumatic disorders among other conditions.[L11994]
Marketing Status approved; vet_approved
ATC Code A07EA04; C05AA05; D07AC01; D07XC01; H02AB01; R01AD06; R03BA04; S01BA06; S01CB04; S02BA07; S03BA03
DrugBank ID DB00443
KEGG ID D00244
MeSH ID D001623
PubChem ID 9782
TTD Drug ID D0CW1P
NDC Product Code 52128-166; 22552-0030; 57582-007; 64958-0012
UNII 9842X06Q6M
Synonyms Betamethasone | Flubenisolone | Betadexamethasone | Celestona | Cellestoderm | Celeston | Celestone
Chemical Information
Molecular Formula C22H29FO5
CAS Registry Number 378-44-9
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypertrophic cardiomyopathy03.07.07.005; 02.04.01.002--Not Available
Hypokalaemic syndrome14.05.03.003--Not Available
Hypopituitarism05.03.02.001--
Hypotension24.06.03.002--
Impaired healing08.03.02.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Increased insulin requirement14.06.01.006; 05.06.01.006--Not Available
Infection11.01.08.002--Not Available
Infection susceptibility increased10.02.01.046; 11.01.08.004--Not Available
Inflammatory bowel disease07.08.01.016--Not Available
Influenza like illness08.01.03.010--
Injection site bruising12.07.03.042; 08.02.03.042; 24.07.06.017; 23.03.11.015--Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.001--Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.005--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intracranial pressure increased17.07.02.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Joint stiffness15.01.02.003--Not Available
Joint swelling15.01.02.004--Not Available
Lacrimation increased06.08.02.004--
Large intestine perforation07.04.06.005; 12.02.03.005--
Leukoderma23.05.02.001--Not Available
Loss of consciousness17.02.04.004--Not Available
Lymphadenopathy01.09.01.002--Not Available
Macule23.03.03.037--Not Available
Malaise08.01.01.003--
Meningitis17.06.03.001; 11.01.03.001--
Menstruation irregular21.01.01.005; 05.05.01.008--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 9 Pages